Abstract
Postmastectomy radiotherapy (PMRT) clearly reduces the risk of local-regional failure (LRF) for patients with invasive breast cancer. However, for many years it has been controversial whether or not this reduction also results in decreased risks of distant failure and, ultimately, death due to cancer. This was largely because randomized trials employing PMRT without systemic therapy did not show improved survival, compared to surgery alone,1–6 with the exception of one trial.7 However, simultaneous publication in the New England Journal of Medicine in October 1997 of two trials routinely employing chemotherapy suddenly brought this debate renewed life.8,9 These studies showed that giving radiation therapy following modified radical mastectomy not only reduced LRF rates but also yielded clinically-relevant improvements in disease-free and overall survival rates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in longterm survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12: 447–453, 1994.
Recht A: The return (?) of postmastectomy radiotherapy (Editorial). J Clin Oncol 13: 2861–2864, 1995.
Harris JR, Morrow M: Local management of invasive breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, J.B. Lippincott, 1996, pp 485–545.
Early Breast Cancer Trialists’ Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 333: 1444–1455, 1995.
Pierce LJ, Lichter AS: Defining the role of post-mastectomy radiotherapy: the new evidence. Oncology (Huntingt) 10: 991–1002, 1996.
Fowble B: Postmastectomy radiotherapy: then and now. Oncology (Huntingt) 11: 213–239, 1997.
Arriagada R, Rutqvist LE, Mattsson A, et al: Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 13: 2869–2878, 1995.
Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337: 949–955, 1997.
Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337: 956–962, 1997.
Recht A, Bartelink H, Fourquet A, et al: Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 16: 2886–2889, 1998.
Recht A: Local-regional failure rates in patients with involved axillary nodes following mastectomy and systemic therapy. Semin Radiat Oncol 9: 223–229, 1999.
Recht A: Postmastectomy loco-regional radiotherapy: is it here to stay? Semin Oncol 2000 (in press).
Blomqvist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicinftorafur) and tamoxifen in Stage II breast cancer. Long-term follow-up results of a randomized trial. Br J Cancer 66: 1171–1176, 1992.
Hayat H, Brufman G, Borovik R, et al: Adjuvant chemotherapy and radiation therapy vs. chemotherapy alone for Stage II breast cancer patients (Abstr.). Ann Oncol 1 (suppl.): 21, 1990.
Griem KL, Henderson IC, Gelman R, et al: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5: 1546–1555, 1987.
Schulz K-D, Reusch K, Schmidt-Rhode P, et al: Consecutive radiation and chemotherapy in the adjuvant treatment of operable breast cancer, in Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer III. New York, Grune & Stratton, 1982, pp 411–418.
Muss HB, Cooper MR, Brockschmidt JK, et al: A randomized study of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer: eleven year follow-up of a Piedmont Oncology Association trial. Breast Cancer Res Treat 19: 77–84, 1991.
Klefström P, Gröhn P, Heinonen E, et al: Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in Stage III breast cancer. Cancer 60: 936–942, 1987.
Gervâsio H, Alves H, Rito A, et al: Phase III study: adjuvant chemotherapy versus adjuvant radiotherapy plus chemotherapy in women with node-positive breast cancer (Abstr.). Breast J 4 (suppl. 1): S88, 1998.
Ahmann DL, O’Fallon JR, Scanlon PW, et al: A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 5: 371–381, 1982.
McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 73: 264–266, 1986.
Vélez-Garcia E, Carpenter JT, Moore M, et al: Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trial. Eur J Cancer 28A: 1833–1837, 1992.
Tennvall-Nittby L, Tenegrup I, Landberg T: The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM Stage II: the South Sweden Breast Cancer Trial. Acta Oncol 32: 641–646, 1993.
Overgaard M, Hansen PS, Overgaard J, et al: Randomized trial evaluating postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Results from the DBCG 82c trial (Abstr.). Radiother Oncol 48 (suppl. 1): S78, 1998.
Olson JE, Neuberg D, Pandya KJ, et al: The role of radiotherapy in the managment of operable locally advanced breast cancer: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79: 1138–1149, 1997.
Whelan T, Wright J, Julian J, et al: Does radiation therapy post-mastectomy improve survival? A meta-analysis (Abstr.). Breast Cancer Res Treat 50: 286, 1998.
Recht A, Hayes DF, Eberlein TJ, et al: Local-regional recurrence after mastectomy or breast-conserving therapy, in Harris JR, Lippman M, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, J.B. Lippincott, 1996, pp 649–667.
Goldhirsch A, Gelber RD, Castiglione M: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6: 89–97, 1988.
Buzdar A, McNeese MD, Hortobagyi GN, et al: Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer 65: 394–399, 1990.
Kaufmann M, Jonat W, Abel U, et al: Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/ tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11: 454–460, 1993.
Chu AM, Kiel K: Comparison of adjuvant postoperative radiotherapy and multiple-drug chemotherapy (CMF-VP) in operable breast cancer patients with more than four positive axillary lymph nodes. Cancer 50: 212–218, 1982.
O’Rourke S, Galea MH, Morgan D, et al: Local recurrence after simple mastectomy. Br J Surg 81: 386–389, 1994.
Pisansky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer 72: 1247–1260, 1993.
Bijker N, Rutgers EJT, Peters JL, et al: Modified radical mastectomy or how to achieve optimal loco-regional control in larger breast cancers (Abstr.). Eur J Surg Onco120: 258, 1994.
Stal O, Sullivan S, Wingren S, et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 2185–2190, 1995.
Zellars RC, Clark GM, Allred DC, et al: Prognostic value of p53 for local failure in mastectomy treated breast cancer patients (Abstr.). Proc Am Soc Clin Oncol 17: 104a, 1998.
Ahlborn TN, Gump FE, Bodian C, et al: Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet 166: 523–526, 1988.
Mentzer SJ, Osteen RT, Wilson RE: Local recurrence and the deep resection margin in carcinoma of the breast. Surg Gynecol Obstet 163: 513–517, 1986.
Freedman GM, Fowble L, Hanlon AL, et al: A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. Int J Radiat Oncol Biol Phys 41: 599–605, 1998.
Fowble B, Gray R, Gilchrist K, et al: Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6: 1107–1117, 1988.
Sykes HF, Sim DA, Wong CJ, et al: Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: evaluation of the role of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 16: 641–647, 1989.
Diab SG, Hilsenbeck SG, deMoor CA, et al: Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16: 1655–1660, 1998.
Recht A, Gray R, Davidson NE, et al: Local-regional failure ten years following mastectomy in patients with histologically involved axillary lymph nodes receiving adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. Submitted for publication.
Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B15. J Clin Oncol 8: 1483–1496, 1990.
Budd GT, Green S, O’Bryan RM, et al: Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an Intergroup study. J Clin Oncol 13: 831–839, 1995.
Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9: 1124–1130, 1991.
Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858–1869, 1997.
Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol 8: 519–526, 1990.
Falkson HC, Gray R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8: 599–607, 1990.
Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 88: 1828–1833, 1996.
Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group: Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 88: 1834–1839, 1996.
Swedish Breast Cancer Cooperative Group: Randomized trial of two years versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543–1549, 1996.
Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) Trial. Eur J Cancer 28: 673–680, 1992.
Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005–1018, 1990.
Pritchard KI, Paterson AHG, Fine S, et al: Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 2302–2311, 1997.
International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patient. Ann Oncol 1: 30–35, 1990.
Stevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300: 1458–1460, 1990.
McQuellon R, Muss H, Hoffman S, et al: The influence of toxicity on treatment preferences of women with breast cancer (Abstr.). Proc Am Soc Clin Oncol 13: 76, 1994.
Whelan TJ, Levine MN, Gafni A, et al: Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol 13: 847853, 1995.
Palda VA, Llewellyn-Thomas HA, Mackenzie RG, et al: Breast cancer patients’ attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol 15: 31923200, 1997.
Hayman JA, Fairclough DL, Harris JR, et al: Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 15: 1252–1260, 1997.
Shapiro CL, Recht A: Late effects of adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 16: 101–112, 1994.
Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis of updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899–909, 1995.
Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467, 1998.
Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930–942, 1998.
Martinez A, Ahmann D, O’Fallon J, et al: An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer (Abstr.). Int J Radiat Oncol Biol Phys 10 (suppl. 2): 106, 1984.
Schmoor C, Bastert G, Bojar H, et al: Effect of radiotherapy in addition to 6 cycles CMF in node positive breast cancer patients (Abstr.). Eur J Cancer 34 (suppl. 5): S59, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Recht, A. (2000). Postmastectomy Radiotherapy. In: Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management. Cancer Treatment and Research, vol 103. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3147-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3147-7_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-3149-1
Online ISBN: 978-1-4757-3147-7
eBook Packages: Springer Book Archive